WishBone Medical Adds Resorbable Implants to its Product Lineup

WishBone Medical has forged a private label distribution agreement with Bone Solutions Inc. (BSI) for worldwide rights within pediatric orthopedics to license and sell OsteoCrete—the first U.S. Food and Drug Administration (FDA) 510k-approved magnesium-based bone void filler in the orthopedic marketspace, designed to assist with bone repair and regeneration. Expanding beyond the original application, OsteoCrete developers are now harnessing the product’s unique properties to create bioresorbable implants to ultimately replace many current metal technologies simultaneously improving patient outcomes.
 
Affording BSI the North American Bone Graft Technology Leadership of the Year Award in 2009, OsteoCrete is an injectable, moldable solution to attach ligaments and tendons to bone, and bone-to-bone, with a robust composition that is three times stronger than cancellous bone.¹
 
“This product is the holy grail for pediatric orthopedics as the resorbable properties eliminate the need for secondary operations,” said WishBone Founder and CEO Nick Deeter. “Kids already harbor a lot of anxieties around the idea of surgery. If we can save patients and their families the expense and worries of follow-up procedures, that alone is a big win.”

BSI surpassed 600 cases implanting OsteoCrete this year with a 100 percent success rate. Moving forward, the company is focused on further development of bioresorbable implants and will continue exploring applications for this orthobiologics technology.
 
“For so many years, the orthopedics industry demonstrated a clear demand for osteogenic implants which mimic properties of the human bone. Prior to OsteoCrete, calcium-based solutions contributed to bone healing, but with little mechanical support,” explained BSI President and CEO Drew Diaz. “Not only is OsteoCrete 100 percent resorbable, it offers excellent bone remodeling during the window of healing with uncompromised strength.”
 
“While patients of all ages and stature benefit from OsteoCrete advancements, the greatest improvement will be felt by children whose bodies are continually growing and changing,” added Kevin Blue, WishBone’s chief revenue officer. “Our team could not be more excited to offer such a clearly advantageous solution to better equip the surgeons caring for them.”
 
WishBone Medical is a global pediatric orthopedic company, committed to providing anatomically appropriate implants and instruments in sterile packed, single-use disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing. Through recent acquisitions, WishBone Medical now offers 42 pediatric orthopedic product systems with operations in Warsaw, Ind.; Istanbul, Turkey; and Singapore.
 
Bone Solutions Inc. is an orthobiologics company with a vision to provide orthopedic surgeons a means to improve clinical outcomes in a number of complex procedures while lowering costs. The company is revolutionizing a new solution for orthopedic surgeons for human uses with its FDA-cleared magnesium-based platform bone void filler.

Reference
¹ Bone Solutions’ Report 755635-01 Rev A, “Static Axial Compression Testing of the OsteoCrete System.”